NCT07358715 Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
| NCT ID | NCT07358715 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National University Hospital, Singapore |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2024-11-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.
Eligibility Criteria
Inclusion Criteria High-Risk Individuals (n = 100) * No prior history of lung cancer * Meets one of the following high-risk definitions: * Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR * Never-smoker aged 55-75 years with a first-degree family history of lung cancer * Able and willing to provide written informed consent Early-Stage Lung Cancer Patients (n = 20) * Aged ≥21 years * Histologically or clinically confirmed stage I-II lung cancer * Treatment-naïve (no prior surgery, chemotherapy, radiotherapy, or immunotherapy for lung cancer) * Able and willing to provide written informed consent Advanced-Stage Lung Cancer Patients (n = 20) * Aged ≥21 years * Histologically or clinically confirmed stage III-IV lung cancer * Treatment-naïve (no prior systemic or local therapy for lung cancer) * Able and willing to provide written informed consent Exclusion Criteria Applicable to All Participants * Pregnant or breastfeeding women * Inability or unwillingness to comply with study procedures High-Risk Individuals Only * Known allergy or contraindication to CT contrast agents * Prior low-dose CT (LDCT), CT thorax, or PET-CT performed within 12 months prior to enrollment Lung Cancer Cohorts Only • Receipt of any prior cancer-directed treatment for lung cancer
Frequently Asked Questions
Who can join the NCT07358715 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 75 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07358715 currently recruiting?
Yes, NCT07358715 is actively recruiting participants. Visit ClinicalTrials.gov or contact National University Hospital, Singapore to inquire about joining.
Where is the NCT07358715 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07358715 clinical trial?
NCT07358715 is sponsored by National University Hospital, Singapore. The trial plans to enroll 140 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.